Crossject
Created in 2001
- BETA
Trend leader (A+)
Existing signals make this entity one of the most dynamic startups Social networks
1,163 5,653Activities
Technologies
Entity types
Location
6 Rue Pauline Kergomard, 21000 Dijon, France
Dijon
France
Employees
Scale: 51-200
Estimated: 95
Engaged corporates
24
9 4Added in Motherbase
3 years, 7 months ago
deeptech Value proposition
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Injection sans aiguile and Traitements d'urgenceOriginal language
Expert des médicaments d'urgence auto-administrés
Crossject SA (Euronext: ALCJ; www.crossject.com) is an emerging specialty pharma company based in France and the U.S. It is in advanced regulatory development for ZEPIZURE®, an epileptic rescue therapy, for which it was awarded a $60 million contract with the U.S. Biomedical Advanced Research and Development Authority (BARDA). ZEPIZURE® is based on the Company’s award-winning needle-free autoinjector ZENEO®, designed to enable patients and untrained caregivers to easily and instantly deliver emergency medication via intramuscular injection on bare skin or even through clothing. The Company’s other products in development include rescue therapies for allergic shocks, adrenal insufficiencies, opioid overdose and asthma attacks.
Crossject | Auto-injection sans aiguille | ZENEO®
Crossject développe un mode d'injection sans aiguille innovant, ZENEO®, plateforme d'injection sans piqûre de solutions médicamenteuses
https://crossject.com/fr/
| Corporate | Type | Tweets | Articles | |
|---|---|---|---|---|
 MEDEF NGO, Think Tank, Civic and Social Organizations | MEDEF NGO, Think Tank, Civic and Social Organizations | Other 27 Sep 2023 | | |
 La Tribune Media, Newspapers | La Tribune Media, Newspapers | Other 1 Sep 2023 | | |
 Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Leem Startup accelerator & VC, Pharmaceutical Manufacturing | Other 13 Mar 2024 | | |
 SAYENS Research, Startup accelerator & VC, Research Services | SAYENS Research, Startup accelerator & VC, Research Services | Other 25 Mar 2023 | | |
 La French Tech Bourgogne-Franche-Comté French Tech, Non-profit Organizations | La French Tech Bourgogne-Franche-Comté French Tech, Non-profit Organizations | Other 5 Dec 2024 | | |
 Dijon métropole Government Administration, French metropolis | Dijon métropole Government Administration, French metropolis | Other 9 Dec 2024 | | |
 PMT Public business cluster, French Cluster, Civic and Social Organizations | PMT Public business cluster, French Cluster, Civic and Social Organizations | Other 15 Jul 2020 12 Dec 2024 | | |
 Bpifrance Bank, Banking | Bpifrance Bank, Banking | Other 6 Mar 2017 15 Jan 2025 | | |
 France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | France Biotech Startup accelerator & VC, Biotechnology, Biotechnology Research | Not capitalistic Not partnership Event 16 Sep 2021 17 Oct 2023 | | |
 Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Région Bourgogne-Franche-Comté National and local authorities, Government Administration | Not capitalistic Partnership Event 21 Jan 2020 17 Nov 2023 | | |